Joseph M.  Beechem net worth and biography

Joseph Beechem Biography and Net Worth

Joseph M. Beechem, Ph.D. has served as our Chief Scientific Officer and Senior Vice President of Research and Development since April 2012. Prior to joining our company, Dr. Beechem held various positions at Life Technologies, a publicly-traded biotechnology tools company, most recently as Vice President, Head of Advanced Sequencing and Head of Global Sequencing Chemistry, Biochemistry and Biophysics from January 2010 to April 2012. From December 2007 to December 2012, he served as Chief Technology Officer of Life Technologies. During his career at Life Technologies, he led the design and development of multiple genetic analysis technologies, the latest advanced SOLiD sequencing technology and the single molecule nano-DNA sequencing technology. Prior to joining Life Technologies, Dr. Beechem was Chief Scientific Officer at Invitrogen, a publicly-traded biotechnology company that acquired Applied Biosystems in November 2008 to form Life Technologies, from August 2003 to December 2007 and Director of Biosciences at Molecular Probes, a biotechnology company acquired by Invitrogen in 2003, from August 2000 to August 2003. Prior to his industry experience, Dr. Beechem led an NIH-funded research laboratory for 11 years as a tenured associate professor at Vanderbilt University. He has authored or co-authored more than 100 peer-reviewed papers in diverse fields such as biomathematics, physics, chemistry, physiology, spectroscopy, diagnostics and biology. Dr. Beechem is also named on nearly 40 U.S. patents or patent applications and has served on a number of editorial and scientific advisory boards. He received a B.S. in Chemistry and Biology from Northern Kentucky University and a Ph.D. in Biophysics from The Johns Hopkins University.

What is Joseph M. Beechem's net worth?

The estimated net worth of Joseph M. Beechem is at least $0.00 as of June 11th, 2021. Dr. Beechem owns 105,034 shares of NanoString Technologies stock worth more than $0 as of December 27th. This net worth approximation does not reflect any other investments that Dr. Beechem may own. Additionally, Dr. Beechem receives an annual salary of $637,410.00 as SVP at NanoString Technologies. Learn More about Joseph M. Beechem's net worth.

How old is Joseph M. Beechem?

Dr. Beechem is currently 66 years old. There are 4 older executives and no younger executives at NanoString Technologies. Learn More on Joseph M. Beechem's age.

What is Joseph M. Beechem's salary?

As the SVP of NanoString Technologies, Inc., Dr. Beechem earns $637,410.00 per year. The highest earning executive at NanoString Technologies is Mr. R. Bradley Gray, CEO, President & Director, who commands a salary of $1,060,000.00 per year. Learn More on Joseph M. Beechem's salary.

How do I contact Joseph M. Beechem?

The corporate mailing address for Dr. Beechem and other NanoString Technologies executives is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. NanoString Technologies can also be reached via phone at (888) 358-6266 and via email at [email protected]. Learn More on Joseph M. Beechem's contact information.

Has Joseph M. Beechem been buying or selling shares of NanoString Technologies?

Joseph M. Beechem has not been actively trading shares of NanoString Technologies during the last ninety days. Most recently, Joseph M. Beechem sold 2,436 shares of the business's stock in a transaction on Tuesday, March 15th. The shares were sold at an average price of $27.81, for a transaction totalling $67,745.16. Learn More on Joseph M. Beechem's trading history.

Who are NanoString Technologies' active insiders?

NanoString Technologies' insider roster includes K. Bailey (CFO), Joseph Beechem (SVP), Elisha Finney (Director), R. Gray (CEO), Robert Hershberg (Director), and Kirk Malloy (Director). Learn More on NanoString Technologies' active insiders.

Joseph M. Beechem Insider Trading History at NanoString Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2022Sell2,436$27.81$67,745.16View SEC Filing Icon  
3/8/2022Sell2,968$33.06$98,122.08View SEC Filing Icon  
9/2/2021Sell23,114$61.14$1,413,189.96View SEC Filing Icon  
6/11/2021Sell131,827$58.94$7,769,883.38105,034View SEC Filing Icon  
See Full Table

Joseph M. Beechem Buying and Selling Activity at NanoString Technologies

This chart shows Joseph M Beechem's buying and selling at NanoString Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NanoString Technologies Company Overview

NanoString Technologies logo
NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.36
Low: $0.05
High: $0.80

2 Week Range

Now: N/A

Volume

23,061,200 shs

Average Volume

34,541,648 shs

Market Capitalization

$5.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24